Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News :

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

United States $10 Billion Generic Injectables Market 2017-2022 - Key Players are Hospira, Hikma, App, Sagent & Sandoz and Henry Shein

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/24/2017 | 10:18am CET

Dublin, Nov. 24, 2017 (GLOBE NEWSWIRE) -- The "US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report has been added to Research and Markets' offering.

The market is projected to reach a value of more than US$ 16 Billion by 2022, growing at a CAGR of around 8% during 2017-2022.

The US generic injectables market reached a value of US$ 10 Billion in 2016, exhibiting a CAGR of more than 9% during 2009-2016. The market growth can be attributed to the low cost of these drugs as compared to their branded counterparts. Moreover, as there is limited price erosion and low competition in the market, the profit margins are significantly higher than commoditised generics.

Generic injectables are widely used in the treatment of various chronic diseases such as cancer, diabetes, cardiovascular diseases, respiratory diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, etc. In the United States, these drugs form an important part of the public healthcare system and contribute in significant savings for the patients and healthcare providers.

Over the next few years, the market is expected to be driven by a number of favourable factors. The cases of chronic diseases have been increasing on account of ageing population, sedentary lifestyles and poor eating habits. This has resulted in a heightened demand for generic injectables. Furthermore, the drug shortages in the country coupled with speedy approvals by the USFDA are expected to boost the manufacturing of these drugs. Additionally, the patent expiry of a large number of branded injectable drugs is expected to support the market growth.

The report has segmented the market on the basis of therapeutic area and covers oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular diseases, etc. Among these, oncology generic injectables represent the largest segment. The report has further analysed the various containers used for generic injectables including vials, premix, prefilled syringes and ampoules. On the basis of distribution channels, the report finds that hospitals dominate the market, accounting for the majority of the share. The report has also examined the competitive landscape of the market and provides the profiles of the key players operative in it.

Some the major players are Hospira, Hikma, App, Sagent, Sandoz and Henry Shein, Inc.

Key Topics Covered:

1 Preface

2 Scope and Methodology
2.1 Objectives of the study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Generic Drug Industry
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Country
5.4 Market Forecast

6 US Generic Drug Industry
6.1 Market Overview
6.2 Market Performance
6.3 Market Forecast

7 US Generic Drug Industry - Drug Delivery Systems
7.1 Orals
7.2 Injectables
7.3 Dermal/Topical
7.4 Inhalers

8 Global Generic Injectables Industry
8.1 Market Overview
8.2 Market Performance
8.3 Market Breakup by Region
8.4 Market Breakup by Therapeutic Area
8.5 Market Breakup by Containers
8.6 Market Breakup by Distribution Channel
8.7 Market Share of Key Players
8.8 Market Forecast

9 US Generic Injectables Industry
9.1 Market Overview
9.2 Market Performance
9.3 Market by Therapeutic Area
9.4 Market by Containers
9.5 Market by Distribution Channel
9.6 Market Share of Key Players
9.7 Market Forecast
9.8 SWOT Analysis
9.9 Value Chain Analysis
9.10 Porters Five Forces Analysis
9.11 Key Success and Risk Factors

10 Market by Therapeutic Area
10.1 Oncology
10.2 Anaesthesia
10.3 Anti-infectives
10.4 Parenteral Nutrition
10.5 Cardiovascular

11 Market by Containers
11.1 Vials
11.2 Ampoules
11.3 Premix
11.4 Prefilled Syringes

12 Market by Distribution Channel
12.1 Hospitals
12.2 Retail Pharmacy

13 US Generic Injectable Market: Competitive Landscape
13.1 Competitive Structure
13.2 Market Breakup by Key Players

14 Generic Injectables Manufacturing Process
14.1 Product Overview
14.2 Detailed Process Flow
14.3 Various Types of Unit Operations Involved
14.4 Mass Balance and Raw Material Requirements

15 Project Details, Requirements and Costs Involved
15.1 Land, Location and Site Development
15.2 Construction Requirements
15.3 Machinery Requirements
15.4 Machinery Pictures
15.5 Raw Materials Requirements
15.6 Raw Material and Final Product Pictures
15.7 Packaging Requirements
15.8 Transportation Requirements
15.9 Product Pricing and Margins Across Various Levels of the Supply Chain

16 Key Players Profiles

  • Hospira
  • Hikma
  • App
  • Sagent
  • Sandoz and Henry Shein, Inc

For more information about this report visit https://www.researchandmarkets.com/research/s9p94q/us_generic


CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Infusions and Injectables 

Primary Logo


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
10:17a VOLKSWAGEN : launches international marketing campaign for new T-Roc
10:17a EVONIK INDUSTRIES : to consolidate its precious metal catalyst activities in India in Catalysts India Pvt. Ltd. (ECI), Dombivli, effective April 1, 2018
10:17a VAST RESOURCES : Open Offer to raise up to 1.23 million
10:17a YOUYUAN INTERNATIONAL : (Revised)Next Day Disclosure Return
10:17a ZTE : Releases Ten Million Users Access vBRAS Solution
10:17a FULLER SMITH & TURNER PLC : - Transaction in Own Shares
10:16a STATOIL : UAE’s Masdar opens 3rd clean energy project in UK
10:16a ORIENTAL WEAVERS CARPET : plans EUR 12m expansions until end-2018
10:16aDJNEWS HIGHLIGHTS : Top Energy News of the Day
10:12a PAYSAFE : Form 8.5 (EPT/RI) - Paysafe Group plc
Latest news
Advertisement